(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid

5 trials 1 recruiting Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

4 Completed trials

3 Sponsors

16 Countries

Phase III

Phase II/III

Phase II

Phase III: 1 Phase II/III: 1 Phase II: 3

Oversight events:

5 temporary halts across 1 trial

View oversight register →

Indications tested

Bladder cancer 1 Pancreatic carcinoma 1 Lung adenocarcinoma 1 Dedifferentiated liposarcoma 1

Sponsors using this IMP

Boehringer Ingelheim International GmbH 4 Boehringer Ingelheim Espana S.A. 3 Institut Bergonie 1

All trials

5 total

A study to test long-term treatment with brigimadlin in people with solid tumours who took part in a previous study with this medicine Recruiting

2024-514177-21-00 Phase II 11 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
EMPIRE : Targeting MDM2 and PD1 in tumors with tertiary lymphoid structures Ended

2023-506823-28-00 Phase II 1 country Institut Bergonie
A study to test whether BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder Ended

2023-506369-79-00 Phase II 5 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…
Brightline-1: A study to compare brigimadlin (BI 907828) with doxorubicin in people with a type of cancer called dedifferentiated liposarcom… Ended

2024-511361-11-00 Phase II/III 12 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
Brightline-4: A study to test how well brigimadlin is tolerated by people with a type of cancer called dedifferentiated liposarcoma Ended

2023-504522-19-00 Phase III 2 countries Boehringer Ingelheim International GmbH

Showing 1–5 of 5 trials

← All drugs A–Z